|
Volumn 97, Issue 5, 2007, Pages 654-658
|
Optimal indications of endocrine therapy alone as adjuvant systemic treatment of breast cancer
|
Author keywords
Adjuvant therapy; Breast cancer; Pathology; St Gallen expert consensus meeting
|
Indexed keywords
TAMOXIFEN;
ADULT;
AGED;
ALGORITHM;
ARTICLE;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER INVASION;
CANCER RECURRENCE;
CANCER RISK;
CANCER SURGERY;
CANCER SURVIVAL;
CLINICAL ASSESSMENT;
CONTROLLED STUDY;
FEMALE;
HORMONAL THERAPY;
HUMAN;
JAPANESE;
LYMPH NODE METASTASIS;
MAJOR CLINICAL STUDY;
MONOTHERAPY;
PRIORITY JOURNAL;
TREATMENT RESPONSE;
VALIDITY;
ADULT;
ANTINEOPLASTIC AGENTS, HORMONAL;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
COMBINED MODALITY THERAPY;
DISEASE-FREE SURVIVAL;
FEMALE;
HUMANS;
IMMUNOHISTOCHEMISTRY;
NEOPLASM RECURRENCE, LOCAL;
RECEPTOR, ERBB-2;
RECEPTORS, ESTROGEN;
RECEPTORS, PROGESTERONE;
RISK FACTORS;
TAMOXIFEN;
TREATMENT OUTCOME;
|
EID: 34548358861
PISSN: 00070920
EISSN: 15321827
Source Type: Journal
DOI: 10.1038/sj.bjc.6603916 Document Type: Article |
Times cited : (5)
|
References (4)
|